Sign Out
Hypersensitivity to budesonide or to one of the other ingredients of Budenofalk. Local intestinal infection (bacteria, fungi, amoebae, viruses).
As with other glucocorticoids, treatment with Budenofalk in patients with severely impaired liver function is associated with a reduced elimination rate and an increase in systemic availability. At the moment, these patients are excluded from budesonide treatment.
Budenofalk may reduce the responsiveness of the hypothalamo-pituitary-adrenocortical axis to stress. Therefore, a systemically acting glucocorticoid should be co-administered in the event eg, of operations or similar stress situations.
Use in children: Because there is no adequate experience, Budenofalk should not be used in children.
